

QuintilesIMS named CRO of the year by F&S

19 October 2016 | News | By BioSpectrum Bureau

QuintilesIMS named CRO of the year by F&S



QuintilesIMS was named Asia Pacific Contract Research Organization (CRO) Company of the Year by Frost & Sullivan, a leading business research and consulting firm. The evaluation used in Frost & Sullivan's selection was conducted before Quintiles and IMS Health merged earlier this month.

"The QuintilesIMS merger is another milestone in Quintiles' history of leadership and innovation," said Rhenu Bhuller, Partner, Transformational Health, Frost & Sullivan. "Biopharma and medtech companies are eager for innovative solutions to the complex challenges they face - especially for evidence supporting outcomes- and value-based care. QuintilesIMS is well-aligned to provide those solutions."

The Frost & Sullivan Company of the Year Award evaluates CROs on visionary innovation and performance as well as customer impact. QuintilesIMS ranked highly in these categories, in particular for pioneering new and complex areas such as regenerative and personalized medicine. With this most recent honor, Quintiles, now QuintilesIMS, has won the F&S CRO Company of the Year award eight times in 10 years.

QuintilesIMS Asia Pacific President Anand Tharmaratnam said: "This award belongs to our dedicated employees, and I believe Asia Pac will be a global leader in 21st century healthcare innovation. I'm excited about the new solutions QuintilesIMS can offer by connecting clinical to commercial to real-world patient outcomes. We are eager to lead Asia Pac's transformation to become a center for healthcare innovation."